Angiomammography for Breast Cancer Response Prediction

N/A

Recruiting

Research Sponsored by CHU de Quebec-Universite Laval

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No evidence of distant metastasis

Histologically proven breast cancer by large gauge needle

Must not have

Significant kidney failure

Frank hyperthyroidism

Timeline

Screening 3 weeks

Treatment Varies

Follow Up cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking at whether a less expensive and more readily available diagnostic modality, namely CESM, is as effective as MRI in predicting the response of a malignant breast tumor to neoadjuvant chemotherapy and the chances of achieving a pCR.

Who is the study for?

This trial is for women over 18 with breast cancer that hasn't spread far (no distant metastasis), measurable by examination. They must be undergoing neoadjuvant chemotherapy, possibly with additional targeted therapy. Exclusions include pregnancy, allergies to contrast dye, MRI contraindications, overt hyperthyroidism, and significant kidney failure.

What is being tested?

The study compares two imaging techniques—CESM and MRI—to see which better predicts the absence of invasive cancer cells in the breast and lymph nodes after early rounds of chemotherapy. This could help switch treatments sooner for those not responding well.

What are the potential side effects?

Potential side effects may relate to the use of contrast dyes during imaging tests such as allergic reactions or kidney issues. The MRI might not be suitable for people with certain implants or claustrophobia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has not spread to distant parts of my body.

Select...

My breast cancer was confirmed with a biopsy.

Select...

My breast tumor can be felt and measured by a doctor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have severe kidney problems.

Select...

I have an overactive thyroid.

Select...

I refuse to undergo a biopsy or surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3. for reporting.